Cipla USA recalls 1% Diclofenac Sodium Topical Gel due to failed pharmaceutical specifications. Consumers should check NDC 76282-103-39 and batch XHBG for affected units.
Failed PH Specifications
Cipla USA is recalling Diclofenac Sodium Topical Gel (1%, 100g) because it failed pharmaceutical specifications. This could lead to unsafe drug levels in the product.
The product failed pharmaceutical specifications, which means it may not contain the correct amount of active ingredient. This could result in ineffective pain relief or potential safety issues.
People who own or use this topical gel for pain relief in the United States. Those with sensitive skin or using the product for extended periods may be at higher risk.
Check for NDC code 76282-103-39 and batch number XHBG on the product label. The gel was manufactured by DPT Laboratories, Ltd. in San Antonio, TX and expires August 31, 2027.
Look for NDC 76282-103-39 and batch XHBG on the gel container.
The recall states the product failed pharmaceutical specifications, but the official notice does not specify if it is safe to use.
Check for NDC code 76282-103-39 and batch number XHBG on the product label.
The recall record does not specify any action steps for consumers.
We’ve drafted a message you can send Cipla to request your refund or repair — edit it as you like.
Subject: Recall D-0291-2026 — Cipla Cipla Hello, I own a Cipla that is covered by recall D-0291-2026 from Cipla. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
